There are five therapies for chronic hepatitis B that are currently approved:
- interferon alfa-2b,
- lamivudine,
- adefovir,
- entecavir and
- pegylated interferon (peginterferon) alfa-2a.
Students found to be infected with a blood-borne virus such as hepatitis B are allowed to continue their medical course leading to full medical registration provided they accept the requirement that they will not be allowed to perform exposure-prone procedures while infectious (HBeAg positive or HBeAg negative with >103 genome equivalents/mL HBV DNA), and that careers in some specialties may not be open to them. Registered medical students who are HBeAg negative and who have virus loads that do not exceed 103 genome equivalents/mL will be tested annually in order to confirm that their virus load has not exceeded the threshold at which they would be prohibited from conducting exposure-prone procedures. Those who have undergone a course of treatment need to show that they have a viral load that does not exceed 103 genome equivalents/mL 1 year after cessation of treatment before a return to unrestricted working practices can be considered.
No comments:
Post a Comment